Total Payments
$744,876
2024 Payments
$69,383
Companies
12
Transactions
331
Payment Breakdown by Category
Consulting$598,945 (80.4%)
Other$110,230 (14.8%)
Travel$32,715 (4.4%)
Food & Beverage$1,848 (0.2%)
Research$1,138 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $598,945 | 181 | 80.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $109,755 | 29 | 14.7% |
| Travel and Lodging | $32,715 | 81 | 4.4% |
| Food and Beverage | $1,848 | 38 | 0.2% |
| Unspecified | $1,138 | 1 | 0.2% |
| Honoraria | $475.40 | 1 | 0.1% |
Payments by Type
General
$743,739
330 transactions
Research
$1,138
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $293,531 | 89 | $0 (2024) |
| Exelixis Inc. | $143,069 | 51 | $0 (2023) |
| Eisai Inc. | $111,495 | 117 | $0 (2021) |
| Merck Sharp & Dohme LLC | $94,332 | 38 | $0 (2024) |
| Janssen Research & Development, LLC | $45,975 | 14 | $0 (2024) |
| PFIZER INC. | $19,850 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $14,862 | 8 | $0 (2018) |
| Acrotech Biopharma Inc. | $10,500 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $6,050 | 1 | $0 (2020) |
| GlaxoSmithKline, LLC. | $3,600 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69,383 | 21 | Merck Sharp & Dohme LLC ($23,028) |
| 2023 | $102,668 | 32 | E.R. Squibb & Sons, L.L.C. ($40,883) |
| 2022 | $71,422 | 33 | E.R. Squibb & Sons, L.L.C. ($32,514) |
| 2021 | $134,891 | 42 | E.R. Squibb & Sons, L.L.C. ($72,584) |
| 2020 | $92,055 | 29 | E.R. Squibb & Sons, L.L.C. ($49,725) |
| 2019 | $47,396 | 35 | E.R. Squibb & Sons, L.L.C. ($21,901) |
| 2018 | $158,248 | 93 | Eisai Inc. ($76,561) |
| 2017 | $68,815 | 46 | Exelixis Inc. ($32,444) |
All Payment Transactions
331 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $5,580.00 | General |
| Category: Oncology | ||||||
| 09/23/2024 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| 09/16/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| 07/22/2024 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/15/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 06/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| 05/28/2024 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 04/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| Category: Oncology | ||||||
| 02/09/2024 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| Category: IMMUNOLOGY | ||||||
| 01/16/2024 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 01/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| 01/10/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $3,507.50 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 12/18/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $3,410.00 | General |
| Category: Oncology | ||||||
| 12/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| 12/08/2023 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Consulting Fee | Cash or cash equivalent | $10,500.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| QEDBGBC2-BGJBC2 | QED Therapeutics, Inc. | $1,138 | 1 |
About Dr. Ronald Bukowski, MD
Dr. Ronald Bukowski, MD is a Hematology & Oncology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952365603.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Bukowski, MD has received a total of $744,876 in payments from pharmaceutical and medical device companies, with $69,383 received in 2024. These payments were reported across 331 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($598,945).
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cleveland, OH
- Active Since 04/12/2006
- Last Updated 01/28/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952365603
Products in Payments
- Lenvima (Drug) $111,495
- OPDIVO (Biological) $85,206
- WELIREG (Drug) $64,783
- CABOMETYX (Drug) $51,575
- Cabometyx (Drug) $48,219
- Cabozantinib (Drug) $35,905
- KEYTRUDA (Biological) $26,049
- LITFULO (Drug) $15,850
- BELEODAQ (Drug) $10,500
- LYNPARZA (Drug) $6,050
- BAVENCIO (Drug) $4,000
- MK-6482 (Drug) $3,500
- OPDUALAG (Drug) $2,325
- TRUSELTIQ (Drug) $1,138
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cleveland
Hillard Lazarus, Md, MD
Hematology & Oncology — Payments: $2.5M
Hematology & Oncology $2.5M
Jorge Garcia, Md, MD
Hematology & Oncology — Payments: $765,093
Hematology & Oncology $765,093
Balazs Halmos, Md, MD
Hematology & Oncology — Payments: $548,525
Hematology & Oncology $548,525
Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $481,414
Hematology & Oncology $481,414
Bachar Dergham, Md, MD
Hematology & Oncology — Payments: $456,653
Hematology & Oncology $456,653
Dr. Brian Hill, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $334,203
Hematology & Oncology $334,203